clinical trials tirzepatide Overview of the SURPASS phase 3 of for the Responsiveness to Tirzepatide vs clinical

Ongoing annual monitoring follows standard care for Hashimoto's, with additional testing if symptoms of thyroid dysfunction develop

What risks deserve careful consideration

Plasma concentrations decline substantially with age, which forms the basis of most regenerative hypotheses about it

Results showed that GLP-1 receptor agonists and SGLT2 inhibitors were superior in reducing the risk of MACE when compared to DPP-4 inhibitors (HR 086 [082089] and 086 [082090], respectively), but no difference was found between SGLT2 inhibitors and GLP-1 receptor agonists in reducing rate of MACE (HR of 101 (094107)) (68)

Trum et al., 2020)